Keywords: USA, FDA, Amgen, Centoroc Ortho, Johnson & Johnson, Aranesp, Procrit, Opogen, Anemia, ESAs

FDA agrees plan requiring Amgen and J&J unit to educate doctors and patients on risks of anemia drugs

Article | 17 February 2010

Print This

Under a plan reached with the US Food and Drug Administration, Amgen and a Johnson & Johnson subsidiary (Centocor Ortho ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in